复发或局部晚期前列腺癌持续雄激素剥夺治疗后的临床结局与睾酮水平:ICELAND 研究的事后分析
ICELAND 研究事后分析纳入接受亮丙瑞林持续雄激素剥夺治疗的局部晚期或复发非转移性前列腺癌患者,按治疗第一年最低、中位和最高睾酮水平分层,发现各睾酮亚组间病因特异性生存率和至前列腺特异性抗原进展时间无差异。
要点
- 持续雄激素剥夺治疗第一年最低、中位和最高血清睾酮≤20 ng/dl 的患者比例分别为 90.1%、83.5% 和 74.5%。
- 按第一年睾酮水平分层的各亚组间,病因特异性生存率和至前列腺特异性抗原(去势抵抗性前列腺癌)进展时间无差异。
- 作者认为该结果可能部分归因于诱导期和亮丙瑞林降低睾酮的有效性。
核心结论
- 在接受持续雄激素剥夺治疗的患者中,治疗第一年的睾酮水平与病因特异性生存率和至前列腺特异性抗原进展时间无差异。
- 作者认为这一发现可能部分归因于诱导期和亮丙瑞林降低睾酮的有效性。
研究设计与样本
- ICELAND 研究(ClinicalTrials.gov NCT00378690)的事后分析,患者为局部晚期或复发非转移性前列腺癌且经亮丙瑞林 3 个月缓释剂 22.5 mg(加比卡鲁胺 50 mg/日共 1 个月)6 个月诱导后前列腺特异性抗原≤1 ng/ml。
- 患者按 1:1 随机接受持续雄激素剥夺治疗(361 例)或间歇雄激素剥夺治疗(340 例),使用亮丙瑞林共 36 个月。
- 接受持续雄激素剥夺治疗的患者按治疗第一年最低、中位和最高睾酮水平分为≤20、>20 至 50 和>50 ng/dl 亚组。
- 分析终点为病因特异性生存率和至前列腺特异性抗原(去势抵抗性前列腺癌)进展时间。
主要发现
- 持续雄激素剥夺治疗组中,最低、中位和最高血清睾酮≤20 ng/dl 的患者比例分别为 90.1%、83.5% 和 74.5%。
- 各睾酮亚组间病因特异性生存率和至前列腺特异性抗原进展时间无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Lower serum testosterone levels correlate with improved cause specific survival and longer time to progression in year 1 of continuous androgen deprivation in men with prostate cancer. ICELAND was a large European study demonstrating the efficacy of leuprorelin (Eligard®) during continuous androgen deprivation. In this post hoc analysis we investigated serum testosterone levels within year 1 of continuous androgen deprivation to determine survival and time to progression. MATERIALS AND METHODS: In ICELAND (ClinicalTrials.gov NCT00378690) patients with locally advanced or relapsing nonmetastatic prostate cancer and with prostate specific antigen 1 ng/ml or less following 6-month induction with leuprorelin 3-month depot 22.5 mg (plus bicalutamide 50 mg per day for 1 month) were randomized 1:1 to continuous androgen deprivation (361) or intermittent androgen deprivation (340) with leuprorelin for 36 months. Patients receiving continuous androgen deprivation were stratified by minimum, median and maximum testosterone levels during year 1 of therapy into 20 or less, greater than 20 to 50 and greater than 50 ng/dl subgroups. Cause specific survival and time to prostate specific antigen (castrate resistant prostate cancer) progression were analyzed. RESULTS: A total of 90.1%, 83.5% and 74.5% of patients receiving continuous androgen deprivation achieved minimum, median and maximum serum testosterone levels of 20 ng/dl or less, respectively. Cause specific survival rates and time to prostate specific antigen progression did not differ among the testosterone subgroups. CONCLUSIONS: In patients receiving continuous androgen deprivation cause specific survival and time to prostate specific antigen progression did not differ according to testosterone levels in year 1 of therapy. This finding may in part be due to the induction period and the effectiveness of leuprorelin in lowering testosterone.
引用
- Tombal B, Cornel EB, Persad R, et al. Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study. J Urol. 2017. PMID: 28552710. doi:10.1016/j.juro.2017.05.072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。